NEW YORK (GenomeWeb) – Alveo Technologies, a pre-clinical stage medical diagnostics firm, announced today that it has raised $38 million in Series A financing.

The Alameda, California-based startup, which was founded in 2014, said it plans to use the funding to advance the optimization and commercialization of its rapid diagnostic platform for infectious diseases. The firm's technology combines nucleic acid detection with molecular biochemistry in order to identify such illnesses.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.